Results 21 to 30 of about 10,060 (149)

Retrospective case series describing the efficacy, safety and cost-effectiveness of a vial-sharing programme for canakinumab treatment for paediatric patients with cryopyrin-associated periodic syndrome

Pediatric Rheumatology Online Journal, 2019
Background Cryopyrin-associated periodic syndrome (CAPS) is a rare autoinflammatory disease, caused by gain of function mutation in NLRP3 resulting in excess production of interleukin-1 (IL-1).
Abdulkadir A. Elmi, Karen Wynne, Iek L. Cheng, Despina Eleftheriou, Helen J. Lachmann, Philip N. Hawkins, Paul Brogan   +6 more
doaj   +1 more source

CANOPY-N: A Phase 2 Study of Canakinumab or Pembrolizumab, Alone or in Combination, as Neoadjuvant Therapy in Patients With Resectable, Stage IB–IIIA NSCLC

JTO Clinical and Research Reports
Introduction: Canakinumab is a human monoclonal anti–interleukin-1β antibody with the potential to enhance the activity of programmed death-ligand 1 inhibitors by inhibiting protumor inflammation.
Jay M. Lee, MD, Jean-Louis Pujol, MD, PhD, Jun Zhang, MD, PhD, Oleg Leonov, MD, PhD, Masahiro Tsuboi, MD, PhD, Edward S. Kim, MD, MBA, Calvin Ng, MD, Nicolas Moreno-Mata, MD, PhD, Amy Cummings, MD, PhD, Ilhan Hacibekiroglu, MD, Abidin Sehitogullari, MD, Nirmal Veeramachaneni, MD, Cathy Spillane, PhD, Jiawei Duan, PhD, Claudia Bossen, PhD, Alexander Savchenko, MD, PhD, Chiara Lobetti-Bodoni, MD, PhD, Tony Mok, MD, Pilar Garrido, MD   +18 more
doaj   +1 more source

Canakinumab [PDF]

Reactions Weekly, 2020
  +7 more sources

Is it possible to extend the dose interval of canakinumab treatment in children with familial Mediterranean fever? PeRA group experience

Pediatric Rheumatology Online Journal, 2023
Background There is no clear data on the optimal duration of treatment with anti-interleukin-1 drugs in colchicine-resistant familial Mediterranean fever patients, as well as on the dose interval.
Gülşah Kavrul Kayaalp, Şengül Çağlayan, Fatma Gül Demirkan, Vafa Guliyeva, Gülçin Otar Yener, Kübra Öztürk, Ferhat Demir, Semanur Özdel, Mustafa Çakan, Hafize Emine Sönmez, Betül Sözeri, Nuray Aktay Ayaz   +11 more
doaj   +1 more source

Cytokine Pathways Driving Diverse Tissue Pathologies in Rheumatoid Arthritis

Arthritis &Rheumatology, EarlyView.
Rheumatoid arthritis (RA) is a complex systemic disorder characterized primarily by articular inflammation and destruction with associated functional loss and reduced quality of life. RA is also associated with extra‐articular disease, such as that of the lung, with potentially devastating clinical consequences. The critical importance of comorbidities,
Aurelie Najm, Lyn D. Ferguson, Iain B. McInnes   +2 more
wiley   +1 more source

Canakinumab for the management of pyoderma gangrenosum: a case series of two patients and literature review

Journal of Dermatological Treatment
Aims To evaluate the efficacy and adverse events of canakinumab in the treatment of pyoderma gangrenosum (PG).Methods We report two cases of refractory PG treated with canakinumab after failing multiple therapies.Results A 44-year-old female achieved ...
Howard Jie Yang, William Spratt, Francis Yi Xing Lai, Senhong Lee   +3 more
doaj   +1 more source

Administration of the Interleukin-1 Inhibitor Canakinumab in Children with Autoinflammatory Diseases and Systemic Juvenile Arthritis: the Report for Case Series

Вопросы современной педиатрии, 2016
In Russia, the interleukin-1 inhibitor canakinumab (fully human monoclonal antibodies to interleukin-1) is increasingly used for treating autoinflammatory diseases and systemic juvenile arthritis (sJIA).
S. O. Salugina, M. I. Kaleda, Ye. S. Fyodorov, I. P. Nikishina   +3 more
doaj   +1 more source

Updated COVID‐19 Vaccines and Health Outcomes in Patients With Autoimmune Rheumatic Conditions

Arthritis &Rheumatology, EarlyView.
Objective We aimed to assess the association between COVID‐19 vaccination status and COVID‐19‐related hospital admissions, need for mechanical ventilation or extracorporeal membrane oxygenation (ECMO), and death in people with autoimmune rheumatic conditions. Methods We conducted a retrospective cohort study using National Clinical Cohort Collaborative
Lesley E. Jackson, A. Jerrod Anzalone, Kenneth G. Saag, Rahima Begum, AKM F. Rahman, Namrata Singh, Kaleb Michaud, Jasvinder A. Singh, Rena C. Patel, Maria I. Danila, on behalf of the National Clinical Cohort Collaborative Consortium, Adam B. Wilcox, Adam M. Lee, Alexis Graves, Alfred (Jerrod) Anzalone, Amin Manna, Amit Saha, Amy Olex, Andrea Zhou, Andrew E. Williams, Andrew M. Southerland, Andrew T. Girvin, Anita Walden, Anjali Sharathkumar, Benjamin Amor, Benjamin Bates, Brian Hendricks, Brijesh Patel, G. Caleb Alexander, Carolyn T. Bramante, Cavin Ward‐Caviness, Charisse Madlock‐Brown, Christine Suver, Christopher G. Chute, Christopher Dillon, Chunlei Wu, Clare Schmitt, Cliff Takemoto, Dan Housman, Davera Gabriel, David A. Eichmann, Diego Mazzotti, Donald E. Brown, Eilis Boudreau, Elaine L. Hill, Emily Carlson Marti, Emily R. Pfaff, Evan French, Farrukh M. Koraishy, Federico Mariona, Fred Prior, George Sokos, Greg Martin, Harold P. Lehmann, Heidi Spratt, Hemalkumar B. Mehta, J. W. Awori Hayanga, Jami Pincavitch, Jaylyn Clark, Jeremy Richard Harper, Jessica Yasmine Islam, Jin Ge, Joel Gagnier, Johanna J. Loomba, John B. Buse, Jomol Mathew, Joni L. Rutter, Julie A. McMurry, Justin Guinney, Justin Starren, Karen Crowley, Katie Rebecca Bradwell, Kellie M. Walters, Ken Wilkins, Kenneth R. Gersing, Kenrick Cato, Kimberly Murray, Kristin Kostka, Lavance Northington, Lee Pyles, Lesley Cottrell, Lili M. Portilla, Mariam Deacy, Mark M. Bissell, Marshall Clark, Mary Emmett, Matvey B. Palchuk, Melissa A. Haendel, Meredith Adams, Meredith Temple‐O'Connor, Michael G. Kurilla, Michele Morris, Nasia Safdar, Nicole Garbarini, Noha Sharafeldin, Ofer Sadan, Patricia A. Francis, Penny Wung Burgoon, Philip R. O. Payne, Randeep Jawa, Rebecca Erwin‐Cohen, Rena C. Patel, Richard A. Moffitt, Richard L. Zhu, Rishikesan Kamaleswaran, Robert Hurley, Robert T. Miller, Saiju Pyarajan, Sam G. Michael, Samuel Bozzette, Sandeep K. Mallipattu, Satyanarayana Vedula, Scott Chapman, Shawn T. O'Neil, Soko Setoguchi, Stephanie S. Hong, Steven G. Johnson, Tellen D. Bennett, Tiffany J. Callahan, Umit Topaloglu, Valery Gordon, Vignesh Subbian, Warren A. Kibbe, Wenndy Hernandez, Will Beasley, Will Cooper, William Hillegass, Xiaohan Tanner Zhang   +127 more
wiley   +1 more source

Lost and found in translation: the value of the human imiquimod model

British Journal of Clinical Pharmacology, EarlyView.
Topical imiquimod (IMQ), a Toll‐like receptor (TLR) 7 agonist, induces transient cutaneous inflammation and is widely used in preclinical research as a ‘psoriasis‐like’ mouse model. However, accumulating evidence indicates substantial divergence between IMQ‐driven biology and human plaque psoriasis pathogenesis.
Anouk C. Meijs, Juliette A. van den Noort, Salma Assil, Naomi B. Klarenbeek, Matthijs Moerland, Tessa Niemeyer‐van der Kolk, Robert Rissmann   +6 more
wiley   +1 more source

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang, Umar Raza, Jia Song, Junyan Lu, Shun Yao, Xiaohong Liu, Wei Zhang, Shujuan Li   +7 more
wiley   +1 more source